Citigroup Inc Amarin Corp Plcuk Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Amarin Corp Plcuk stock. As of the latest transaction made, Citigroup Inc holds 7,105 shares of AMRN stock, worth $3,552. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,105

Previous 8,467 16.09%

Holding current value

$3,552

Previous $5,000 20.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$0.57 - $0.8 $776 - $1,089	-1,362 Reduced 16.09%	7,105 $4,000
Q2 2024 Aug 12, 2024	BUY	$0.63 - $1.07 $4,433 - $7,530	7,038 Added 492.51%	8,467 $5,000
Q1 2024 May 10, 2024	SELL	$0.82 - $1.35 $4,552 - $7,495	-5,552 Reduced 79.53%	1,429 $1,000
Q4 2023 Feb 09, 2024	BUY	$0.66 - $0.91 $1,453 - $2,003	2,202 Added 46.08%	6,981 $6,000
Q3 2023 Nov 09, 2023	SELL	$0.85 - $1.43 $1,473 - $2,478	-1,733 Reduced 26.61%	4,779 $4,000
Q2 2023 Aug 10, 2023	BUY	$1.12 - $1.49 $2,425 - $3,227	2,166 Added 49.84%	6,512 $7,000
Q1 2023 May 11, 2023	SELL	$1.19 - $2.19 $598 - $1,101	-503 Reduced 10.37%	4,346 $6,000
Q4 2022 Feb 09, 2023	BUY	$1.07 - $1.34 $428 - $536	400 Added 8.99%	4,849 $5,000
Q3 2022 Nov 10, 2022	SELL	$1.09 - $1.67 $33,899 - $51,937	-31,100 Reduced 87.48%	4,449 $5,000
Q2 2022 Aug 10, 2022	SELL	$1.13 - $3.69 $1,672 - $5,461	-1,480 Reduced 4.0%	35,549 $53,000
Q1 2022 May 12, 2022	BUY	$2.85 - $3.73 $72,304 - $94,630	25,370 Added 217.6%	37,029 $122,000
Q4 2021 Feb 10, 2022	SELL	$3.24 - $5.18 $33,060 - $52,856	-10,204 Reduced 46.67%	11,659 $39,000
Q3 2021 Nov 10, 2021	BUY	$3.94 - $5.84 $86,140 - $127,679	21,863 New	21,863 $112,000

Others Institutions Holding AMRN

# of Institutions

176

Shares Held

65.1M

Call Options Held

258K

Put Options Held

98K

View Full List

About AMARIN CORP PLCUK

Ticker AMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 403,206,016
Market Cap $202M
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...

More about AMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account